AAPL347.73-0.50 (-0.14%) ▼|ABBV285.64+0.45 (+0.16%) ▲|ABT103.70+1.19 (+1.16%) ▲|ACN249.37-9.37 (-3.62%) ▼|ADBE263.82-6.73 (-2.49%) ▼|AMAT377.24+1.66 (+0.44%) ▲|AMD516.79+8.86 (+1.74%) ▲|AMGN439.26-8.02 (-1.79%) ▼|AMT188.97+7.40 (+4.08%) ▲|AMZN248.00-2.38 (-0.95%) ▼|AVGO321.68-1.56 (-0.48%) ▼|AXP313.22-11.95 (-3.68%) ▼|BA188.35+0.80 (+0.43%) ▲|BAC50.56-0.52 (-1.02%) ▼|BKNG155.83-5.27 (-3.27%) ▼|BLK1,118.25-19.04 (-1.67%) ▼|BMY61.48-1.52 (-2.41%) ▼|BNY145.27-0.05 (-0.03%) ▼|BRK-B542.19-4.78 (-0.87%) ▼|C120.62-1.89 (-1.54%) ▼|CAT687.00-17.05 (-2.42%) ▼|CL94.04-3.35 (-3.44%) ▼|CMCSA22.69-0.15 (-0.66%) ▼|COF201.34-2.09 (-1.03%) ▼|COP150.80+5.17 (+3.55%) ▲|COST1,003.32-14.89 (-1.46%) ▼|CRM248.57-1.72 (-0.69%) ▼|CSCO106.50+1.61 (+1.53%) ▲|CVS93.47-1.01 (-1.07%) ▼|CVX233.21+6.53 (+2.88%) ▲|DE646.15+2.53 (+0.39%) ▲|DHR230.50+0.75 (+0.33%) ▲|DIS112.52-0.61 (-0.54%) ▼|DUK124.98-0.42 (-0.33%) ▼|EMR161.59+1.30 (+0.81%) ▲|FDX298.72-5.20 (-1.71%) ▼|GD349.36-1.43 (-0.41%) ▼|GE285.64-7.90 (-2.69%) ▼|GEV815.00-12.42 (-1.50%) ▼|GILD156.04-1.15 (-0.73%) ▼|GM75.92-1.29 (-1.67%) ▼|GOOG317.28-3.48 (-1.08%) ▼|GOOGL320.21-4.01 (-1.24%) ▼|GS875.68-15.62 (-1.75%) ▼|HD319.83-7.90 (-2.41%) ▼|HON221.15+2.84 (+1.30%) ▲|IBM253.56+1.45 (+0.58%) ▲|INTC86.96+1.47 (+1.72%) ▲|INTU343.39-11.51 (-3.24%) ▼|ISRG452.29+8.44 (+1.90%) ▲|JNJ263.81-3.80 (-1.42%) ▼|JPM331.58-4.96 (-1.47%) ▼|KO92.71-2.63 (-2.76%) ▼|LIN508.83-1.53 (-0.30%) ▼|LLY1,273.46-33.23 (-2.54%) ▼|LMT604.18+14.27 (+2.42%) ▲|LOW198.68-5.69 (-2.78%) ▼|LRCX230.10-0.05 (-0.02%) ▼|MA623.60-9.61 (-1.52%) ▼|MCD248.46-4.17 (-1.65%) ▼|MDLZ63.80-1.39 (-2.13%) ▼|MDT95.41-1.18 (-1.22%) ▼|META642.62-6.23 (-0.96%) ▼|MMM173.46-2.10 (-1.20%) ▼|MO74.31-1.76 (-2.31%) ▼|MRK145.27-1.97 (-1.34%) ▼|MS179.49-4.48 (-2.44%) ▼|MSFT524.51+3.43 (+0.66%) ▲|MU877.55+21.06 (+2.46%) ▲|NEE82.10+0.20 (+0.24%) ▲|NFLX65.85-1.20 (-1.79%) ▼|NKE37.30-1.02 (-2.66%) ▼|NOW158.96+1.96 (+1.25%) ▲|NVDA210.96-1.25 (-0.59%) ▼|ORCL126.16+0.62 (+0.49%) ▲|PEP135.77-3.06 (-2.20%) ▼|PFE30.03-0.39 (-1.28%) ▼|PG161.02-3.48 (-2.12%) ▼|PLTR196.75+0.56 (+0.29%) ▲|PM199.47-2.27 (-1.13%) ▼|QCOM175.91+3.08 (+1.78%) ▲|RTX191.01-3.70 (-1.90%) ▼|SBUX100.80-1.11 (-1.09%) ▼|SCHW90.58-0.86 (-0.94%) ▼|SO92.89-0.93 (-0.99%) ▼|SPG211.63-0.41 (-0.19%) ▼|T20.93-1.81 (-7.96%) ▼|TMO673.82-2.72 (-0.40%) ▼|TMUS146.54-12.25 (-7.71%) ▼|TSLA372.22-2.36 (-0.63%) ▼|TXN284.69+5.19 (+1.86%) ▲|UBER66.70-2.37 (-3.43%) ▼|UNH418.09-6.89 (-1.62%) ▼|UNP292.87-5.22 (-1.75%) ▼|UPS101.06-0.46 (-0.45%) ▼|USB59.58-0.44 (-0.73%) ▼|V407.92-6.42 (-1.55%) ▼|VZ44.66-0.54 (-1.19%) ▼|WFC82.39-0.62 (-0.75%) ▼|WMT119.89-1.23 (-1.02%) ▼|XOM183.21+4.98 (+2.79%) ▲|AAPL347.73-0.50 (-0.14%) ▼|ABBV285.64+0.45 (+0.16%) ▲|ABT103.70+1.19 (+1.16%) ▲|ACN249.37-9.37 (-3.62%) ▼|ADBE263.82-6.73 (-2.49%) ▼|AMAT377.24+1.66 (+0.44%) ▲|AMD516.79+8.86 (+1.74%) ▲|AMGN439.26-8.02 (-1.79%) ▼|AMT188.97+7.40 (+4.08%) ▲|AMZN248.00-2.38 (-0.95%) ▼|AVGO321.68-1.56 (-0.48%) ▼|AXP313.22-11.95 (-3.68%) ▼|BA188.35+0.80 (+0.43%) ▲|BAC50.56-0.52 (-1.02%) ▼|BKNG155.83-5.27 (-3.27%) ▼|BLK1,118.25-19.04 (-1.67%) ▼|BMY61.48-1.52 (-2.41%) ▼|BNY145.27-0.05 (-0.03%) ▼|BRK-B542.19-4.78 (-0.87%) ▼|C120.62-1.89 (-1.54%) ▼|CAT687.00-17.05 (-2.42%) ▼|CL94.04-3.35 (-3.44%) ▼|CMCSA22.69-0.15 (-0.66%) ▼|COF201.34-2.09 (-1.03%) ▼|COP150.80+5.17 (+3.55%) ▲|COST1,003.32-14.89 (-1.46%) ▼|CRM248.57-1.72 (-0.69%) ▼|CSCO106.50+1.61 (+1.53%) ▲|CVS93.47-1.01 (-1.07%) ▼|CVX233.21+6.53 (+2.88%) ▲|DE646.15+2.53 (+0.39%) ▲|DHR230.50+0.75 (+0.33%) ▲|DIS112.52-0.61 (-0.54%) ▼|DUK124.98-0.42 (-0.33%) ▼|EMR161.59+1.30 (+0.81%) ▲|FDX298.72-5.20 (-1.71%) ▼|GD349.36-1.43 (-0.41%) ▼|GE285.64-7.90 (-2.69%) ▼|GEV815.00-12.42 (-1.50%) ▼|GILD156.04-1.15 (-0.73%) ▼|GM75.92-1.29 (-1.67%) ▼|GOOG317.28-3.48 (-1.08%) ▼|GOOGL320.21-4.01 (-1.24%) ▼|GS875.68-15.62 (-1.75%) ▼|HD319.83-7.90 (-2.41%) ▼|HON221.15+2.84 (+1.30%) ▲|IBM253.56+1.45 (+0.58%) ▲|INTC86.96+1.47 (+1.72%) ▲|INTU343.39-11.51 (-3.24%) ▼|ISRG452.29+8.44 (+1.90%) ▲|JNJ263.81-3.80 (-1.42%) ▼|JPM331.58-4.96 (-1.47%) ▼|KO92.71-2.63 (-2.76%) ▼|LIN508.83-1.53 (-0.30%) ▼|LLY1,273.46-33.23 (-2.54%) ▼|LMT604.18+14.27 (+2.42%) ▲|LOW198.68-5.69 (-2.78%) ▼|LRCX230.10-0.05 (-0.02%) ▼|MA623.60-9.61 (-1.52%) ▼|MCD248.46-4.17 (-1.65%) ▼|MDLZ63.80-1.39 (-2.13%) ▼|MDT95.41-1.18 (-1.22%) ▼|META642.62-6.23 (-0.96%) ▼|MMM173.46-2.10 (-1.20%) ▼|MO74.31-1.76 (-2.31%) ▼|MRK145.27-1.97 (-1.34%) ▼|MS179.49-4.48 (-2.44%) ▼|MSFT524.51+3.43 (+0.66%) ▲|MU877.55+21.06 (+2.46%) ▲|NEE82.10+0.20 (+0.24%) ▲|NFLX65.85-1.20 (-1.79%) ▼|NKE37.30-1.02 (-2.66%) ▼|NOW158.96+1.96 (+1.25%) ▲|NVDA210.96-1.25 (-0.59%) ▼|ORCL126.16+0.62 (+0.49%) ▲|PEP135.77-3.06 (-2.20%) ▼|PFE30.03-0.39 (-1.28%) ▼|PG161.02-3.48 (-2.12%) ▼|PLTR196.75+0.56 (+0.29%) ▲|PM199.47-2.27 (-1.13%) ▼|QCOM175.91+3.08 (+1.78%) ▲|RTX191.01-3.70 (-1.90%) ▼|SBUX100.80-1.11 (-1.09%) ▼|SCHW90.58-0.86 (-0.94%) ▼|SO92.89-0.93 (-0.99%) ▼|SPG211.63-0.41 (-0.19%) ▼|T20.93-1.81 (-7.96%) ▼|TMO673.82-2.72 (-0.40%) ▼|TMUS146.54-12.25 (-7.71%) ▼|TSLA372.22-2.36 (-0.63%) ▼|TXN284.69+5.19 (+1.86%) ▲|UBER66.70-2.37 (-3.43%) ▼|UNH418.09-6.89 (-1.62%) ▼|UNP292.87-5.22 (-1.75%) ▼|UPS101.06-0.46 (-0.45%) ▼|USB59.58-0.44 (-0.73%) ▼|V407.92-6.42 (-1.55%) ▼|VZ44.66-0.54 (-1.19%) ▼|WFC82.39-0.62 (-0.75%) ▼|WMT119.89-1.23 (-1.02%) ▼|XOM183.21+4.98 (+2.79%) ▲|
16.1 C
New York
Saturday, October 24, 2026

Tag: medication

Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results

Ifetroban was well tolerated in patients with systemic sclerosis NASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-driven biopharmaceutical company...

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie’s SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn’s Disease

Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the...

UCB Establishes the Emmanuel Janssen Endowed Chair for the Evaluation of Medicines at Brigham and Women’s Hospital

Permanent endowment advances pharmacoepidemiology and real-world evidence researchSebastian Schneeweiss, MD, ScD, an internationally recognized pharmacoepidemiologist whose research focuses on improving medication safety, effectiveness, and...

Alebund Pharmaceuticals Announces Poster Presentation by Partner R1 Therapeutics of Global Phase IIb Multi-Regional Clinical Trial Design for AP306 at ASN Kidney Week 2026

SHANGHAI, Oct. 23, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that its...

NUH OPHTHALMOLOGY AT 40: FOUR DECADES OF TRANSFORMING EYE CARE

The Department marks its anniversary by spotlighting innovations in multidisciplinary and minimally invasive care, alongside a flagship international congress that fosters global collaboration in...

Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis

The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patients in ChinaCAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 22, 2026...

AceMyNursingExams Launches Online Exam Prep for Nursing Students

The platform offers practice questions, study guides and answer explanations for nursing entrance, school and licensure exams.HOUSTON, Oct. 22, 2026 /PRNewswire/ -- AceMyNursingExams today...

National Kidney Foundation Highlights New Blood Pressure Guidance Putting Kidney Health at the Forefront

New KDOQI commentary emphasizes early kidney testing, accurate blood pressure measurement, and individualized careNEW YORK, Oct. 22, 2026 /PRNewswire/ -- The National Kidney Foundation...

Ping An Unveils China’s First Brain Health Service Management Program, Focused on Alzheimer’s Prevention and Care

HONG KONG and SHANGHAI, Oct. 22, 2026 /PRNewswire/ -- On 21 October, Ping An Insurance (Group) Company of China ("Ping An") unveiled China's first...

Therakos Receives MDR Approval in Europe for Treating Immune-Related Adverse Events in Patients with Inadequate Response to Corticosteroids

DUBLIN, Oct. 22, 2026 /PRNewswire/ -- Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal photopheresis (ECP), announced...

Therakos Receives MDR Approval in Europe for Treating Immune-Related Adverse Events in Patients with Inadequate Response to Corticosteroids

DUBLIN, Oct. 21, 2026 /CNW/ -- Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal photopheresis (ECP), announced...

Therakos Receives MDR Approval in Europe for Treating Immune-Related Adverse Events in Patients with Inadequate Response to Corticosteroids

DUBLIN, Oct. 21, 2026 /PRNewswire/ -- Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal photopheresis (ECP), announced...

Xcellerant Ventures Invests $1M in Geneticure to Advance Precision Medicine and Expand Arizona’s Biotech Hub

Precision medicine pioneer to establish new clinical lab in Arizona, bringing predictive testing for renal denervation to marketSCOTTSDALE, Ariz., Oct. 21, 2026 /PRNewswire/ --...

Early LGS-CORE Registry Data Show Only 4% of Reported Treatments Stopped All Seizures in Lennox-Gastaut Syndrome

SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- The Lennox-Gastaut Syndrome (LGS) Foundation will present the first data from its LGS Collaborative Outcomes Registry (LGS-CORE)...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedication